
The vaccine cut the risk of melanoma recurrence or death, but Moderna shares fell as investors weighed expectations and pipeline risks.
Moderna and Merck said their Phase 3 melanoma trial found that adding Moderna’s personalized cancer vaccine to Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. Moderna shares fell sharply after the results, which may have failed to meet high investor expectations.
The study included 1,137 patients. At two years, 82.2% of patients receiving the combination had not had a recurrence, compared with 70.0% in the Keytruda-only group. At 13:54 UTC Monday, Moderna shares were at $200.85, up 0.37% from the previous close.
BioNTech said its Phase 3 ROSETTA Breast-01 study will switch, subject to regulatory approval, to testing pumitamig with Gilead’s Trodelvy. The company also reported that its BNT113 study in HPV16-positive head and neck cancer missed its primary endpoint; the trial continues to assess overall survival.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.